MHRA issued a Class 4 medicines defect notification for Ponlimsi (Denosumab) 60mg solution for injection (Teva UK Ltd).
Class 4 defect notifications indicate a potential quality issue that does not pose a serious risk to patient safety but requires action to ensure product integrity and correct usage.
Check stock for the affected batches of Ponlimsi (Denosumab) 60mg solution for injection and follow the instructions in the MHRA notice.
Regulatory Intelligence Lead
Immediate review and action; monitor for updates from MHRA.
HCPs should note the labeling error. Ensure correct administration (subcutaneous). Report any adverse reactions via Yellow Card.
Check stock for the affected batches of Ponlimsi (Denosumab) 60mg solution for injection and follow the instructions in the MHRA notice.
The MHRA published a Class 4 medicines defect notification for Teva UK Ltd's Ponlimsi (Denosumab) 60mg solution for injection in pre-filled syringes. Healthcare professionals should check their stock for affected batches and follow instructions in the notice.
What changed: MHRA issued a Class 4 medicines defect notification for Ponlimsi (Denosumab) 60mg solution for injection (Teva UK Ltd).
Why it matters: Class 4 defect notifications indicate a potential quality issue that does not pose a serious risk to patient safety but requires action to ensure product integrity and correct usage.
Practical implication: Check stock for the affected batches of Ponlimsi (Denosumab) 60mg solution for injection and follow the instructions in the MHRA notice.
Published from the Firecrawl agent regulatory extraction pipeline.
Review and update labeling processes in accordance with the newly published safety-related changes for affected products.
MAHs must allocate resources to develop and maintain SPPs, ensuring they meet the new regulatory requirements and are ready for submission within two days upon request in crisis situations.
Implementation of new dosing schedules and an emphasis on monitoring for potential adverse reactions as outlined in the prescribing information.
Regulatory compliance processes may need updates to incorporate the new recombinant endotoxins testing method and guidelines established under the ICMRA framework.
